Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165482 | 0.85 | KCNJ1 (0.52) | KCNJ1LMNAKMT2AALDH1A1MAPT | |
| SCHEMBL2713824 | 0.79 | JUN (0.40) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL380569 | 0.79 | JUN (0.45) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL21935846 | 0.79 | KCNJ1 (0.44) | KCNJ1ALDH1A1NNMTKDM1ANPC1 | |
| SCHEMBL724089 | 0.79 | JUN (0.45) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL64708 | 0.77 | NNMT (0.53) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL31753297 | 0.77 | NNMT (0.53) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL15375575 | 0.77 | JUN (0.37) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL9924106 | 0.77 | JUN (0.37) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL18339567 | 0.77 | JUN (0.41) | JUNNFKB1NFKB2RELALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| CN-119684303-A | Heterocyclic compound of difunctional degradable androgen receptor and application thereof | 上海超阳药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025036132-A1 | COMPOUND AND USE THEREOF | 中国海洋大学 | 2025-02-20 | — | — | WO | disclosed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
| US-12043612-B2 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same | ARVINAS OPERATIONS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024033454-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| US-20110039848-A1 | FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110039848-A1 | FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2272844-A1 | FIVE-MEMBERED RING COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| WO-2010141273-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141273-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2009134392-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2005092304-A2 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0989986-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | Abbott Laboratories (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1998046605-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | JUN 2708/4885NFKB1 3711/4885NFKB2 3757/4885 |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | JUN 4426/4885NFKB1 1950/4885NFKB2 1926/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | JUN 4426/4885NFKB1 1950/4885NFKB2 1926/4885 |
| US-12043612-B2 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same | PAICS, UGT1A1, PBRM1 | JUN 2733/4885NFKB1 1661/4885NFKB2 2624/4885 |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | JUN 2857/4885NFKB1 69/4885NFKB2 155/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | JUN 4426/4885NFKB1 1950/4885NFKB2 1926/4885 |
| US-20110039848-A1 | FIVE-MEMBERED RING COMPOUND | IL5, EPX, CCL11 | JUN 880/4885NFKB1 265/4885NFKB2 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.